The novel adjuvant dmLT promotes dose sparing, mucosal immunity and longevity of antibody responses to the inactivated polio vaccine in a murine model
Open Access
Abstract
No abstract availableKeywords
Funding Information
- Bill and Melinda Gates Foundation (OPP1031440)
This publication has 31 references indexed in Scilit:
- Priming after a Fractional Dose of Inactivated Poliovirus VaccineNew England Journal of Medicine, 2013
- The A Subunit of Escherichia coli Heat-Labile Enterotoxin Functions as a Mucosal Adjuvant and Promotes IgG2a, IgA, and Th17 Responses to Vaccine AntigensInfection and Immunity, 2012
- Bioencapsulation of the hepatitis B surface antigen and its use as an effective oral immunogenVaccine, 2012
- Transcutaneous immunization as preventative and therapeutic regimens to protect against experimental otitis media due to nontypeable Haemophilus influenzaeMucosal Immunology, 2011
- Characterization of a Mutant Escherichia coli Heat-Labile Toxin, LT(R192G/L211A), as a Safe and Effective Oral AdjuvantClinical and Vaccine Immunology, 2011
- A Unique Role of the Cholera Toxin A1-DD Adjuvant for Long-Term Plasma and Memory B Cell DevelopmentThe Journal of Immunology, 2011
- Intradermal delivery of vaccines: potential benefits and current challengesBulletin of the World Health Organization, 2011
- Toward the development of a stable, freeze-dried formulation of Helicobacter pylori killed whole cell vaccine adjuvanted with a novel mutant of Escherichia coli heat-labile toxinVaccine, 2010
- Preexisting Poliovirus‐Specific IgA in the Circulation Correlates with Protection against Virus Excretion in the ElderlyThe Journal of Infectious Diseases, 2008
- Virus Excretion after Mass Vaccination with Attenuated Polioviruses in HungaryBMJ, 1961